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ABSTRACT 
Currently, filtration surgery has been considered as the most effective therapy for glaucoma; however, the 
scar formation in the surgical area may often lead to failure to the procedure. An implanted drug delivery 
system may provide localized and sustained release of a drug over an extended period. Poly (ethylene 
glycol)-poly (ε-caprolactone)-poly (ethylene glycol) (PEG-PCL-PEG, PECE) hydrogel has been successfully 
synthesized and determined as thermosensitive and biocompatible. In order to overcome the limitations of 
common local ophthalmic medications, we investigated the function of a self-assembled PECE hydrogel as 
an intracameral injection-implanted drug carrier to inhibit the formation of postoperative scarring. 
Following bevacizumal-loaded hydrogel intracameral injection into rabbit eyes,  the status of the bleb and 
filtration fistula formed following the filtering surgery were examined through pathologic evaluation. Due 
to the sustained release of bevacizumab from the hydrogel, neovascularization and scar formation were 
inhibited; moreover, there were no corneal abnormalities and other ocular tissue damage found in the 
rabbits. This suggests that the PECE hydrogel may be considered as the novel biomaterial with potential as 
a sustained release system in glaucoma filtering surgery. Further studies require in shedding the light on 
the subject. 
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INTRODUCTION 
Glaucoma is one of the major causes of irreversible 
blindness in the world and is usually associated with 
increased intraocular pressure (IOP) (1,2). Glaucoma 
filtration surgery is performed by creating a fistula 
between the subconjunctival space and the anterior 
chamber to allow the drainage of aqueous humor into 
the filtering bleb, resulting in lowering the IOP (3). 
Modulation of wound healing is critical to ensure 
successful surgery. Unfortunately, glaucoma filtration 
surgery fails in 30–50% of patients because of fibroblast 
proliferation and collagen deposition at the site of the 
filtration bleb, preventing further drainage of aqueous 
humor (4). There are many ophthalmic drug delivery 
systems that can be used following filtration surgery. 
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Conventional delivery systems such as eye drops, 
ointments, or suspensions are the most preferred routes 
of administration to the anterior segment of the eye. The 
bioavailability of topical instillation of drugs is, however, 
usually low since the absorption of eye drops is severely 
limited by the relatively impermeable cornea. 
Additionally, multiple subconjunctival and intracameral 
injections of antiscarring drugs following glaucoma 
filtering surgery are often required to maintain a high 
drug concentration (5). Moreover, not only are the 
frequent injections inconvenient and uncomfortable for 
the patient, but these agents can also cause cell 
apoptosis and death. This injection process is usually 
associated with several undesirable complications such 
as corneal epithelial defects, cataracts, endophthalmitis 
and other ocular diseases (6). Frequent instillation of 
concentrated solutions is required to achieve the desired 
therapeutic effects. There are few satisfactory 
treatments due to the lack of an ideal drug delivery 
system. We may need a novel and promising ophthalmic 
drug delivery system for these diseases. As it is a new 
biomaterial, a biodegradable poly (PEG-PCL-PEG, PECE) 
triblock copolymer was successfully synthesized, 
resulting in a flowing solution at low temperatures that 
turned into a nonflowing gel at body temperature (1). 
The PECE hydrogel applied through intracameral 
injection could be a novel vector for an ophthalmic drug 
delivery system and gene therapy. Bevacizumab 
(Avastin), a synthetic monoclonal antibody used against 
vascular endothelial growth factor (anti-VEGF), was 
reported to limit scar formation following glaucoma 
filtration surgery and to effectively decrease patients’ 
IOP (7,8). Several reports have described the successful, 
off-label intravitreal use of bevacizumab for treatment of 
neovascularization associated with proliferative diabetic 
retinopathy, age-related macular degeneration, and 
neovascular glaucoma (9,10). Furthermore, bevacizumab 
may be a beneficial agent for limiting scar tissue 
formation and thereby improving success following 
filtration surgery (11). 
 
Is the hydrogel an ideal drug delivery system? 
It is obvious that the inhibition of scar tissue formation is 
limited while the bevacizumab is directly administrated 
through intracameral injection and subsequently rapidly 
eliminated from the body. Therefore, a suitable 
container allowing sustained release of bevacizumab is 
needed. In clinical application, ocular anterior segment 
implanted biomaterials should ideally meet the following 
qualities: (a) the implanted materials should be injectable 
and the process of implantation simple, moreover, they 
should have certain viscoelasticity and keep flowing in 
the ocular anterior segment; (b) the implanted materials 
should be non-immunogenic to not cause inflammation 
and foreign body adverse reactions; (c) the implanted 
materials should completely degrade over a certain time 
and the materials from the degradation process can be 
an effectively controlled drug release into the anterior 
chamber to cure ocular diseases. 
  To date, various drug delivery devices such as 
biodegradable amphiphilic block copolymers have been 
synthesized and applied as drug delivery systems (12-14). 
For local sustainable release of therapeutic agents, 
hydrogels are the preferred choice due to their good 
biodegradability, biocompatibility, huge drug capacity 
and response to the physical/chemical stimulus (15,16). 
Hydrogels have been studied extensively in various 
applications such as medical devices and drug delivery 
system (17,18). The gelation of hydrogel in the body may 
lower the rate of diffusion of the entrapped drug 
following being loaded with therapeutic agents, which 
enhances the drug retention and bioavailability (19). 
Furthermore, injectable hydrogels would be in a soluble 
form prior administration in the body, however once 
administered, undergo gelation in situ to form a gel. The 
porous structure of hydrogels makes them perfect 
carriers for therapeutic macromolecules, such as protein, 
RNA or DNA. Hydrogel can also be used as a nonviral 
gene delivery vehicle. It is reported that supercoiled 
pDNA entrapped in hydrogel expressed maximally at one 
day and lasted for three days (20,21). For the 
macrostructure of bevacizumab, the hydrogel systems 
are suitable carriers for its sustainable delivery. 
Additionally, because of its thermoresponsive 
characteristic, the hydrogel can be injected in a liquid 
form to the juxtascleral region or the vitreous cavity via a 
small-gauge needle. This system is designed to optimize 
the antiangiogenic effects and minimize the potential 
ectopic effects of a large bolus delivery (22). 
Thermosensitive hydrogels therefore have great 
potential in the topical delivery of bevacizumab. 
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  Recently, a series of block copolymers consisting of PEG 
and PCL or PLA, which can form micelles by self-
assembling, or thermosensitive hydrogels have been 
widely reported (23,24). Based on the PEG as the 
hydrophilic segment, and PCL or PLA as hydrophobic 
segment, different kinds of hydrogels can be formed that 
include PCEC hydrogel, PECE hydrogel, PLA-PEG-PLA 
hydrogel and PEG-PLA hydrogel. Among these, PECE 
hydrogel contains the basic components of PEG and PCL, 
which are biocompatible and have been used in several 
Food and Drug Administration-approved products. For 
instance, the in vivo gel formation and degradation 
behavior were noted by subcutaneously injecting 
aqueous PECE solution into mice. The PECE hydrogel was 
also an effective, safe, and convenient agent for 
preventing post-surgical intra-abdominal adhesions, and 
was proved to be safe in BALB/c mice in vivo by acute 
toxicity testing (25,26). Consequently, the PECE hydrogel 
is believed to be promising for in situ gel-forming 
controlled drug delivery systems that are injectable 
flowing solutions at low temperature but that turn into 
gel at body temperature in vivo (27). The good sustained 
release properties of hydrogels have been confirmed in 
vitro. The sol–gel–sol transition temperature range could 
be varied, and the prepared PECE hydrogels have proved 
to be thermosensitive, biocompatible, and bioabsorbable 
(28). With further consideration of the loading and 
releasing properties of PECE hydrogel to small molecules, 
such as HK, curcumin, DOX, cisplatin and so forth, it is 
rational to predict that this hydrogel will exhibit excellent 
performance in the topical delivery of bevacizumab. We 
have hypothesized that it could be delivered in a liquid 
form, which is much more convenient and also 
temperature-sensitive, then it could form a gel in situ 
and release drugs continuously after intraocular injection 
or instillation.  Furthermore, ocular tissues could absorb 
the PECE hydrogel completely without any permanent 
damage. PECE hydrogel may be an implanted drug 
delivery system for the inhibition of postoperative 
scarring formation.  
 
METHODS 
The PECE hydrogel has great biocompatibility, 
biodegradability, and sustained release properties in the 
eye and it is hoped it will be a creative and promising 
ophthalmic drug delivery system in the future. So we 
speculate that PECE hydrogel through intracameral 
injection is as a novel potential, in situ, sustained 
ophthalmic drug delivery system that can be applied to 
prevent scarring formation after trabeculectomy. 
However, the toxicity of PECE hydrogel was 
concentration-dependent according to our pilot study 
with different concentrations (5 wt %, 10 wt %, 15 wt % 
and 20 wt %). Endothelia of rabbits were treated with 5 
wt %, 10 wt% and 15 wt% PECE hydrogel seemed regular. 
However, 5 wt% and 10 wt% PECE hydrogel were not 
conducive to sustained release, because they were 
degraded more early than 15 wt% PECE hydrogel. In 
addition, 20 wt% PECE hydrogel could result in 
endothelial injury more severely than 15 wt% PECE 
hydrogel. We eventually found that the slight toxicity of 
15 wt% PECE hydrogel is reasonable.  
  PECE triblock copolymer was dissolved in a balanced salt 
solution (BSS) at a designated temperature and at the 
concentration of 15 wt% to form PECE hydrogels; these 
PECE hydrogels were then kept at 4° C before being used 
(28). In the self-assembly process hydrogel can be 
directly loaded with appropriate drugs. We loaded 
bevacizumab into the hydrogel, building a bevacizumab 
controlled-release system, and applied this kind of 
controlled-release system following filtration surgery 
through intracameral injections into rabbit eyes. Bleb 
survival and characteristics were evaluated over a 28-day 
period. The rabbits were sacrificed with an overdose of 
pentobarbital on the 28th day. Histology of the surgical 
eyes was performed to evaluate and grade the amount 
of scarring and fibrosis in each group. 
 
RESULTS 
The rabbits’ eyes were examined carefully to detect the 
toxic effect of PECE hydrogel on ocular tissues and to 
evaluate the biocompatibility of novel hydrogel following 
injection into the rabbits’ anterior chambers. In the 
whole experimental process, the rabbits’ anterior 
chambers that were injected PECE hydrogels did not 
show any corneal abnormalities, cataract, inflammatory 
signs, or other ocular disorders by slit-lamp 
biomicroscopy and indirect ophthalmoscopy. 
Bevacizumab could be administered slowly, smoothly 
and efficiently by release from a hydrogel controlled-
release system. In the anterior chamber, PECE hydrogel 
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on the corneal endothelia burst into fragments on 
contact with the aqueous humor because of hydrolysis. 
Hydrogel was absorbed completely within 3 weeks 
(Figure 1). These phenomena indicated water gel injected 
in rabbit eyes with good biocompatibility. We also tested 
the high IOP of eyes that had been injected with 
bevacizumab-loaded hydrogel and found that the 
anterior chamber injected bevacizumab-loaded hydrogel 
maintained relatively lower IOP, compared with the 
Bevacizumab group and BSS group following 
trabeculectomy (Table 1). We speculated that following a 
bevacizumab-loaded hydrogel injection into the anterior 
chamber of rabbits, the main degradation products, as a 
single amino acid, had non-toxic side effects on the 
trabecular meshwork cells in rabbit eyes. In addition, 
there was a period of time for hydrogel degradation, so 
PECE hydrogel released bevacizumab constantly to 
encourage antiscar formation and control IOP in rabbit 
eyes. We will evaluate this hypothesis in the future since 
this study has been performed as a pilot report. Finally, 
the pathological tissue slices of the injected eyes, 
including the cornea, lens, iris, ciliary body and retina and 
found there were no tissue anomalies. The structure of 
each layer of the above tissues showed no infiltration by 
inflammatory cells or obvious irritations to rabbit eyes 
(data not shown). Dual staining of corneal endothelium 
with Typan blue and Alizarin red was also performed. The 
rabbits’ endothelial cells were nearly a regular hexagon 
shape and intact following the bevacizumab-loaded 
hydrogel intracameral injection (Figure 2). Repeated 
measures ANOVA was analyzed (F=10.135, P=0.012), 
suggesting that the difference between the three groups 
was statistically significant. Then we found there was no 
significant difference between BSS group and 
Bevacizumab group, while a significant decrease in IOP 
was found in the Bevacizumab-loaded hydrogel group 
compared with the BSS group or Bevacizumab group   (P 
<0.01 and P <0.05, respectively) (n=3 rabbit in each 
group). 
 
Figure 1. In vivo gel formation of PECE hydrogel in the rabbit 
anterior chamber. PECE was absorbed completely within 3 
weeks. A: 1d after injection. B: 7d after injection. C: 14d after 
injection D: 21d after injection (× 40 magnification). 
 
Figure 2. Combined staining of rabbit endothelia with Typan 
blue and alizarin red after PECE injection into anterior chamber. 
Staining of intercellular borders with alizarin red showed the 
mosaic pattern of normal cells and low proportion of dead cells. 
A: control eye without treatment B: PECE-bevacizumab 
injection eye (×400 magnification) 
 





1(d) 3(d) 7(d) 14(d) 21(d) 28(d) 
BSS Group 16.997±0.335 14.773±0.836  15.000±0.000  14.773±0.510 14.887±0.196 15.443±0.510 15.220±0.191  
Bevacizuma
b Group 





16.667±0.557  15.553±0.508  14.887±0.196  14.220±0.191  13.443±0.510  13.110±0.840  12.997±0.335  
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DISSCUSSION 
To assess whether these PECE hydrogel applications 
through intracameral injection can be a sustained and 
secure ophthalmic drug delivery system in clinical 
practice, further studies on toxicity evaluation could be 
conducted. More evidence on the ocular drug delivery 
nanocarriers with antiscarring drugs following glaucoma 
filtration surgery will support our hypothesis. Hydrophilic 
agents can easily mix with hydrogel and form sustained 
release medications. Intracameral injection of hydrogel 
at relatively low concentration has little effect on cell 
viability, IOP and histopathology of ocular tissues in 
toxicity evaluation (28). This is especially useful for 
antiscarring treatment after glaucoma filtration surgery 
in clinical practice. Although, there are many anatomical 
differences between rabbit and human eyes (29), the 
overall pattern of wound healing is similar to scars found 
in humans (30). As a result, intracameral injection of 
drug-loaded hydrogel could avoid the need for frequent 
subconjunctival injections and decrease the toxic ocular 
side effects caused by intraoperative topical applications. 




The results indicated that PECE hydrogel is of good 
biodegradability and biocompatibility when injected into 
the anterior chamber of rabbits. The drug-loaded 
hydrogels provide a great opportunity to increase the 
therapeutic efficacy of glaucoma filtration surgery. This 
technique not only avoids frequent subconjunctival or 
intracameral injection of drugs given thereby significantly 
reducing the side effects of drugs on the surrounding 
normal tissue, but can also control the filtration 
postoperative IOP and inhibit filtration postoperative 
scarring and neovascularization. These findings indicate 
its potential application in ophthalmology as an 
implantable drug delivery system for the treatment to 
ocular anterior segment diseases in the future. 
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